- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02056769
CT Perfusion Imaging to Predict Vasospasm in Subarachnoid Hemorrhage (CT-PIPS)
Studienübersicht
Status
Intervention / Behandlung
Detaillierte Beschreibung
Rupture of a brain aneurysm results in a type of bleeding into the brain called subarachnoid hemorrhage (SAH). This is a substantial cause of morbidity and mortality world-wide: even with the best possible care, up to half of patients die and many are left disabled. Sometimes this is because the immediate brain damage from the bleed is very severe. However, many patients who seem to be doing well at first go on to develop something called "vasospasm": narrowing of large arteries in the brain. This results in the brain not getting enough blood, and the patient can suffer a stroke as a result. The lack of blood to the brain is called delayed cerebral ischemia (DCI), and is the major secondary cause of stroke and death in patients who survived the initial aneurysm rupture.
Vasospasm can be seen on angiograms (blood vessel imaging) in about two-thirds of SAH patients, and causes neurological symptoms of DCI in half of those patients. It usually develops about a week or so after SAH. Early diagnosis and treatment of cerebral vasospasm and delayed cerebral ischemia (DCI) reduces morbidity and mortality in SAH patients.
CT perfusion imaging is able to identify areas of reduced cerebral blood flow that are at risk of DCI and stroke. This technique is able to measure cerebral blood flow and blood volume (CBF, CBV), and calculates two other measures of cerebral perfusion: time to peak intensity (TTP) and mean transit time (MTT). Taken together, these provide information about the amount of blood the brain is receiving and whether the brain is compensating for any reduction in flow. This is helpful because seeing vasospasm on imaging is not enough to predict brain ischemia and stroke; the additional physiological information provided by the perfusion assessment strengthens the diagnosis of DCI. Early evidence suggests that CT perfusion is a fast, accurate, inexpensive and non-invasive method of brain imaging to identify patients with DCI after SAH, and guide appropriate therapy.
If we were able to successfully predict which patients are at high risk of DCI and/or stroke, we could intervene early. This could improve patient outcomes, while potentially allowing better use of limited intensive care and nursing resources. Other studies have shown that patients with DCI had altered perfusion prior to developing clinical symptoms, but we do not know whether we can use CT perfusion to predict patients at risk, or which CT perfusion measurements (e.g., CBF or TTP) are most useful.
The radiation risk associated with CT perfusion imaging is negligible, due to advances in CT technology which allow for routine simultaneous CT perfusion and CT angiogram (CTA) without a significant increase in radiation dose over conventional head CT-CTA alone. Judicious use of CT perfusion, through a structured algorithm that includes routine perfusion scans at admission and during the peak risk period for vasospasm, may actually decrease cumulative radiation dose for patients with SAH, by ruling out perfusion deficit and brain ischemia as a cause of decreased neurological function and limiting repeated angiograms.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 3A7
- Halifax Infirmary, Capital District Health Authority
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Patient is between 18 and 75 years of age (inclusive).
- Patient has a documented aneurysmal SAH.
- Patient or next of kin or person with appropriate power of attorney has provided written informed consent.
- Patient is willing and available for study follow-up visits.
- Patient has not been previously entered into this study.
Exclusion Criteria:
- Inability to obtain informed written consent.
- Patient is < 18 or > 75 years old.
- Patient is not expected to survive >24 hours (e.g. those presenting with loss of brain stem reflexes, or patients transferred to the Halifax Infirmary ICU for consideration of organ donation rather than active treatment)
- Patient history indicates high risk of non-compliance (e.g., substance abuse, psychosocial issues, etc.)
- Patient is currently breast feeding, or pregnant
- Patient is currently enrolled in another clinical study (device or drug).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: DIAGNOSE
- Zuteilung: N / A
- Interventionsmodell: SINGLE_GROUP
- Maskierung: KEINER
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
EXPERIMENTAL: CT Perfusion
All patients enrolled in the study
|
Quantitative CT Perfusion imaging
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
CBF Admit
Zeitfenster: Baseline
|
Cerebral blood flow as measured on CT perfusion study on admission
|
Baseline
|
CBV Admit
Zeitfenster: Baseline
|
Cerebral blood volume as measured on CT perfusion study on admission
|
Baseline
|
MTT Admit
Zeitfenster: Baseline
|
Mean transit time as measured on CT perfusion study on admission
|
Baseline
|
TTP Admit
Zeitfenster: Baseline
|
Time to peak as measured on CT perfusion study on admission
|
Baseline
|
CBF day 6
Zeitfenster: Day 6 post-SAH
|
Cerebral blood flow as measured on CT perfusion study on day 6 following subarachnoid hemorrhage
|
Day 6 post-SAH
|
CBV day 6
Zeitfenster: Day 6 post-SAH
|
Cerebral blood volume as measured on CT perfusion study on day 6 following subarachnoid hemorrhage
|
Day 6 post-SAH
|
MTT day 6
Zeitfenster: Day 6 post-SAH
|
Mean transit time as measured on CT perfusion study on day 6 following subarachnoid hemorrhage
|
Day 6 post-SAH
|
TTP day 6
Zeitfenster: Day 6 post-SAH
|
Time to peak as measured on CT perfusion study on day 6 following subarachnoid hemorrhage
|
Day 6 post-SAH
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Radiation Dose
Zeitfenster: 30 days post-SAH
|
Total cumulative radiation dose from cranial imaging (CT Head, CT angiogram, CT perfusion, catheter angiography, endovascular coiling) during the initial hospital admission for SAH, up to 30 days post-SAH.
|
30 days post-SAH
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Delayed Cerebral Ischemia
Zeitfenster: 30 days post-SAH
|
Delayed cerebral ischemia is defined using a consensus recently agreed upon by an international panel of experts: namely, 1) stroke seen on CT or MRI scan, or proven at autopsy (not including stroke related to the aneurysm treatment), or 2) clinical deterioration presumed to be caused by DCI after other causes are excluded.
|
30 days post-SAH
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Gwynedd E Pickett, MD, Capital District Health Authority, Halifax, Canada
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (TATSÄCHLICH)
Primärer Abschluss (TATSÄCHLICH)
Studienabschluss (ERWARTET)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (SCHÄTZEN)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (TATSÄCHLICH)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Nekrose
- Herz-Kreislauf-Erkrankungen
- Gefäßerkrankungen
- Zerebrovaskuläre Erkrankungen
- Erkrankungen des Gehirns
- Erkrankungen des zentralen Nervensystems
- Erkrankungen des Nervensystems
- Infarkt
- Streicheln
- Hirninfarkt
- Intrakranielle Blutungen
- Ischämie des Gehirns
- Ischämie
- Blutung
- Hirninfarkt
- Subarachnoidalblutung
- Vasospasmus, intrakranial
Andere Studien-ID-Nummern
- CT-PIPS
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur CT Perfusion
-
University of ManitobaCanadian Institutes of Health Research (CIHR)Abgeschlossen
-
University of PittsburghBeendetKarzinom, nicht kleinzellige LungeVereinigte Staaten
-
University of ManitobaManitoba Medical Service FoundationAbgeschlossen
-
Nova Scotia Health AuthorityUnbekannt
-
Jai ShankarUnbekannt
-
UMC UtrechtDutch Heart FoundationUnbekannt
-
Memorial Sloan Kettering Cancer CenterAbgeschlossenHirntumorVereinigte Staaten
-
University Hospital, BrestRekrutierungLungenembolie | DyspnoeFrankreich
-
Radboud University Medical CenterDutch Cancer SocietyRekrutierungPDAC – duktales Adenokarzinom der BauchspeicheldrüseNiederlande
-
Stanford UniversityGE Healthcare; Siemens Corporation, Corporate TechnologyBeendetNeuroendokrine Tumoren | Darmkrebs | Dickdarm-/Rektalkrebs | Leber | Hirntumoren (Nervensystem). | Leber- und Gallenkrebs | Hepatozelluläres Karzinom (Hepatom)Vereinigte Staaten